GE HealthCare Technologies Inc. is a global medical technology company providing advanced imaging, ultrasound, patient care, and pharmaceutical diagnostic solutions. The company operates through four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Its product portfolio includes magnetic resonance, computed tomography, molecular imaging, X-ray, and ultrasound systems, along with AI-enabled software and cloud services. GE HealthCare serves hospitals, health systems, and researchers globally. The company was spun off from General Electric Company in January 2023.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage gehealthcare.com
Sector Healthcare IR page investor.gehealthcare.com
Tags
medical imaging, ultrasound, magnetic resonance, computed tomography, molecular imaging, pharmaceutical diagnostics, ai software, clinical workflow, patient care, diagnostic imaging, Verisound, Vscan, Centricity, Datalogue, Command Center, Imaging 360, CareIntellect, MTAS, STRATUM, Heartbeat
Press page gehealthcare.com/en-us/about/newsroom

Metrics

Valuation  
Market cap $ 29.556B
Market cap (USD) $ 29.556B
P/E 13.82
PEG 4.86
P/BV 2.54
P/S 1.37
P/OCF 14.87
P/FCF 19.64
Dividend yield 0.21%
Turnover / mcap —
Returns  
ROE 22.1%
ROI 10.2%
ROIC 10.6%
Profit margin 10.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 2.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 85.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 102
Quality score 55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 20.625B 19.672B 19.552B 18.341B 17.585B
Net profit 2.084B 1.993B 1.568B 1.916B 2.247B
Free cash flow 1.505B 1.554B 1.714B 1.803B 1.359B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 82.02 78.18 77.32 58.38 —
Price performance 12m 0.05 0.01 0.32 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 22M 1.01B 3B 1.01B
Borrowings, non-current (USD) — — 8.23B 8.44B 7.45B 9.5B
Lease liabilities (USD) — — 347M 421M 425M 460M
Cash and deposits (USD) 1.01B 561M 1.44B 2.49B 2.87B 4.49B
Intangible assets (USD) — — 1.52B 1.25B 1.08B 1.13B
Right-of-use assets (USD) — — 313M 356M 364M 410M
Net debt (borrowings + leases - cash) (USD) — — 7.16B 7.37B 8B 6.47B
Cash flow detail
Operating cash flow (USD) — 1.61B 2.13B 2.1B 1.96B 1.99B
Purchases of property, plant and equipment (USD) — -248M -310M -387M -401M -482M
Change in inventories (cash effect) (USD) — -435M -402M 111M -81M -142M
Change in payables (cash effect) (USD) — 263M 481M -13M 126M 90M
Dividends paid (cash effect) (USD) — 0.00 0.00 -41M -55M -64M
Share buybacks (cash effect) (USD) — — — 0.00 0.00 -200M
Interest paid (cash effect) (USD) — -21M 0.00 -570M -550M -522M
Income taxes paid (cash effect) (USD) — -615M -851M -474M -491M -429M
Share-based compensation (USD) — 76M 67M 114M 125M 130M
Free cash flow (OCF - PPE - intangibles) (USD) — 1.36B 1.82B 1.71B 1.55B 1.51B
Income detail
Research and development expense (USD) — 816M 1.03B 1.21B 1.31B 1.26B
Total comprehensive income (USD) — 2.1B 1.12B 764M 1.36B 2.13B
Comprehensive income to owners (USD) — 2.05B 1.07B 755M 1.31B 2.07B
Provision for credit losses (USD) — 12M 2M 16M 20M 10M
Reported Feb 6, 2024 Feb 6, 2024 Feb 6, 2024 Feb 4, 2026 Feb 4, 2026 Feb 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 4, 2026, Taha Kass-Hout notified GE HealthCare Technologies Inc. (“GE HealthCare”) that he will resign as Chief Science and Technology Officer. Mr. Kass-Hout’s last day at GE HealthCare will be December 31, 2026.

November 03, 2026

  • New AI-assisted capabilities expand the Vscan Air suite with lung scan guidance and support for the assessment of moderate-to-severe aortic stenosis

CHICAGO — November 3, 2026 — GE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air™ handheld ultrasound system: Lung Guidance and AutoAS.[1
] Designed for clinicians evaluating patients with cardiac and respiratory symptoms at the point of care, these innovations are intended to support consistent lung ultrasound image acquisition and provide additional insights for the assessment of moderate-to-severe aortic stenosis (AS).

Patients presenting with symptoms such as shortness of breath can require clinicians to consider cardiac, pulmonary or overlapping causes, often in time-pressured settings where formal imaging or specialist interpretation may not be immediately available. The Vscan Air cardiopulmonary suite of AI solutions, which already includes Caption AI™ for cardiac scan guidance and Caption Interpretation™ Auto EF (ejection fraction) interpretation support, now expands to assist users with Lung Guidance for pulmonary assessment support, and AutoAS for the assessment of valve disease. Together, the suite is designed to bring additional information closer to the initial point of assessment, helping clinicians build consistency, clarity and confidence as they determine appropriate next steps in care.

“Clinicians at the point of care are often working with limited time and incomplete information, and a symptom like shortness of breath rarely announces if it’s coming from the heart, the lungs, or both,” said Karley Yoder, Chief Executive Officer, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. “Lung Guidance and AutoAS are designed to shorten the distance between the initial physical assessment and a clear next step, putting AI-enabled tools in the hands of the clinician who is already with the patient.”

Supporting more consistent lung ultrasound acquisition

Lung Guidance provides real-time scan guidance to help clinicians optimize probe position and acquire diagnostic-quality lung images by guiding them to correct anatomical landmarks in each zone of the standard 8-zone lung protocol. The system helps guide image acquisition through the detection of lung landmarks including the pleural line, A-lines, rib shadows, diaphragm and abdomen.

When predefined landmark and image-quality criteria are met, AutoCapture automatically records an ultrasound clip. A Save Best Clip feature also allows users to retain the best quality image from each view during scanning when AutoCapture conditions are not achieved. Lung Guidance additionally supports B-line detection and scoring, as well as reporting to help clinicians organize findings from the acquired lung ultrasound exam.

In validation testing, Lung Guidance enabled non-expert lung ultrasound users to consistently acquire diagnostic-quality lung ultrasound exams, with 95.2 percent success compared with 96.8 percent for expert users, per a descriptive assessment.[2
]

AI-assisted aid for assessing moderate/severe aortic stenosis

AutoAS is designed to provide an AI-assisted automated visual estimate of the presence or absence of moderate-to-severe AS using standard 2D cardiac images acquired with Vscan Air SL. With at least two compatible standard echocardiographic views—parasternal long-axis (PLAX), parasternal short-axis at the aortic valve (PSAX-AV) or apical five-chamber (AP5)—AutoAS analyzes the images and provides an estimate indicating whether findings are suggestive of moderate-to-severe AS, along with a confidence score indicating the algorithm’s certainty.

AutoAS is designed to support a clinician’s early assessment of AS when access to formal echocardiography may be delayed.[3]   AutoAS was trained and validated against a reference panel of expert cardiologists and can reduce the variability of missed AS compared to visual interpretation alone.[4]

Together, Lung Guidance and AutoAS build on Vscan Air’s existing AI capabilities, including Caption AI and Auto Bladder Volume, and reflect GE HealthCare’s efforts to support the confident use of ultrasound by more users. GE HealthCare continues to activate AI solutions across its extensive point-of-care ultrasound portfolio, including Venue™ family systems, LOGIQ™ e family and Vscan Air, meeting the needs of large healthcare systems, individual physicians, and everyone in-between.

Lung Guidance and AutoAS are 510(k) cleared by the U.S. Food and Drug Administration and CE marked, and are available for purchase through Vscan Air Innovation Packages in the United States and select countries. Existing Vscan Air customers with a valid Innovation Package subscription or license are expected to receive these updates by the end of November 2026. Offerings vary by location and system model.

News Release Bull 2 Bear 0 Product/operations

GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments

November 3, 2026

PDF Version

New AI-assisted capabilities expand the Vscan Air suite with lung scan guidance and support for the assessment of moderate-to-severe aortic stenosis

CHICAGO--(BUSINESS WIRE)--Nov. 3, 2026-- GE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air™ handheld ultrasound system: Lung Guidance and AutoAS.1 Designed for clinicians evaluating patients with cardiac and respiratory symptoms at the point of care, these innovations are intended to support consistent lung ultrasound image acquisition and provide additional insights for the assessment of moderate-to-severe aortic stenosis (AS).

Patients presenting with symptoms such as shortness of breath can require clinicians to consider cardiac, pulmonary or overlapping causes, often in time-pressured settings where formal imaging or specialist interpretation may not be immediately available. The Vscan Air cardiopulmonary suite of AI solutions, which already includes Caption AI™ for cardiac scan guidance and Caption Interpretation™ Auto EF (ejection fraction) interpretation support, now expands to assist users with Lung Guidance for pulmonary assessment support, and AutoAS for the assessment of valve disease. Together, the suite is designed to bring additional information closer to the initial point of assessment, helping clinicians build consistency, clarity and confidence as they determine appropriate next steps in care.

“Clinicians at the point of care are often working with limited time and incomplete information, and a symptom like shortness of breath rarely announces if it’s coming from the heart, the lungs, or both,” said Karley Yoder, Chief Executive Officer, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. “Lung Guidance and AutoAS are designed to shorten the distance between the initial physical assessment and a clear next step, putting AI-enabled tools in the hands of the clinician who is already with the patient.”

Supporting more consistent lung ultrasound acquisition

Lung Guidance provides real-time scan guidance to help clinicians optimize probe position and acquire diagnostic-quality lung images by guiding them to correct anatomical landmarks in each zone of the standard 8-zone lung protocol. The system helps guide image acquisition through the detection of lung landmarks including the pleural line, A-lines, rib shadows, diaphragm and abdomen.

When predefined landmark and image-quality criteria are met, AutoCapture automatically records an ultrasound clip. A Save Best Clip feature also allows users to retain the best quality image from each view during scanning when AutoCapture conditions are not achieved. Lung Guidance additionally supports B-line detection and scoring, as well as reporting to help clinicians organize findings from the acquired lung ultrasound exam.

In validation testing, Lung Guidance enabled non-expert lung ultrasound users to consistently acquire diagnostic-quality lung ultrasound exams, with 95.2 percent success compared with 96.8 percent for expert users, per a descriptive assessment.2

AI-assisted aid for assessing moderate/severe aortic stenosis

AutoAS is designed to provide an AI-assisted automated visual estimate of the presence or absence of moderate-to-severe AS using standard 2D cardiac images acquired with Vscan Air SL. With at least two compatible standard echocardiographic views—parasternal long-axis (PLAX), parasternal short-axis at the aortic valve (PSAX-AV) or apical five-chamber (AP5)—AutoAS analyzes the images and provides an estimate indicating whether findings are suggestive of moderate-to-severe AS, along with a confidence score indicating the algorithm’s certainty.

AutoAS is designed to support a clinician’s early assessment of AS when access to formal echocardiography may be delayed.3 AutoAS was trained and validated against a reference panel of expert cardiologists and can reduce the variability of missed AS compared to visual interpretation alone.4

Together, Lung Guidance and AutoAS build on Vscan Air’s existing AI capabilities, including Caption AI and Auto Bladder Volume, and reflect GE HealthCare’s efforts to support the confident use of ultrasound by more users. GE HealthCare continues to activate AI solutions across its extensive point-of-care ultrasound portfolio, including Venue™ family systems, LOGIQ™ e family and Vscan Air, meeting the needs of large healthcare systems, individual physicians, and everyone in-between.

Lung Guidance and AutoAS are 510(k) cleared by the U.S. Food and Drug Administration and CE marked, and are available for purchase through Vscan Air Innovation Packages in the United States and select countries. Existing Vscan Air customers with a valid Innovation Package subscription or license are expected to receive these updates by the end of November 2026. Offerings vary by location and system model.

Prompts

GE HealthCare Technologies Inc. (ticker GEHC), listed in United States.

Company History

Date Change Detail
Aug 25, 2022 Renamed GE Healthcare Holding LLC → GE HEALTHCARE TECHNOLOGIES INC.

ETFs Holding GE HealthCare Technologies Inc.

ETF Weight in ETF Shares Market value As of
LGHT 5.41% 2,091 $ 133.845K Jun 30, 2026
PINK 2.18% 89,245 $ 7.304M Nov 17, 2026
TCAL 1.66% 66,224 $ 5.494M Nov 17, 2026
HWSM 1.57% 674 $ 43.143K Jun 30, 2026
KNO 1.38% 9,796 $ 627.042K Jun 30, 2026
ABCS 1.38% 2,417 $ 172.163K Aug 31, 2026
JHAC 0.98% 540 $ 34.565K Jun 30, 2026
PSET 0.96% 4,342 $ 277.931K Jun 30, 2026
CGVV 0.76% 18,610 $ 1.544M Nov 16, 2026
CSTK 0.73% 18,949 $ 1.289M Jul 31, 2026
JAVA 0.60% 550,943 $ 45.089M Nov 17, 2026
MCDS 0.54% 521 $ 42.639K Nov 17, 2026
FEMV 0.50% 410 $ 26.244K Jun 30, 2026
FPAG 0.49% 41,587 $ 2.662M Jun 30, 2026
SROI 0.47% 1,292 $ 87.882K Jul 31, 2026
BAMV 0.40% 6,495 $ 462.639K Aug 31, 2026
DFLV 0.37% 352,024 $ 28.81M Nov 12, 2026
BTAL short -0.37% -16,192 $ -1.036M Jun 30, 2026
JSTC 0.32% 11,339 $ 940.683K Nov 17, 2026
CDX 0.30% 8,950.5711 $ 732.515K Nov 17, 2026
MEDX 0.28% 840 $ 53.768K Jun 30, 2026
AIVL 0.25% 16,275 $ 1.042M Jun 30, 2026
ESUM 0.24% 6,513 $ 443.014K Jul 31, 2026
LSVD 0.24% 22,900 $ 1.558M Jul 31, 2026
FMDE 0.23% 264,646 $ 16.94M Jun 30, 2026
AVMC 0.22% 14,404 $ 1.195M Nov 16, 2026
CLSE short -0.22% -27,626 $ -1.968M Aug 31, 2026
FTLS short -0.21% -66,567 $ 0.00 Nov 16, 2026
DFUV 0.18% 335,469 $ 27.455M Nov 12, 2026
DFVX 0.14% 9,939 $ 813.408K Nov 12, 2026
GMOV 0.14% 2,116 $ 150.723K Aug 31, 2026
TUGN 0.13% 1,681 $ 107.601K Jun 30, 2026
CAPE 0.13% 4,996 $ 319.794K Jun 30, 2026
FLSP 0.12% 17,309 $ 1.108M Jun 30, 2026
TUG 0.10% 560 $ 35.846K Jun 30, 2026
DXUV 0.10% 75,488 $ 6.178M Nov 12, 2026
GVLU 0.09% 2,854 $ 236.768K Nov 17, 2026
DFSU 0.08% 23,669 $ 1.937M Nov 12, 2026
XMAG 0.08% 2,109 $ 172.601K Nov 13, 2026
TACU 0.07% 151 $ 12.527K Nov 17, 2026
SEIV 0.07% 15,576 $ 997.02K Jun 30, 2026
DFAU 0.07% 105,018 $ 8.595M Nov 12, 2026
DFAC 0.06% 681,761 $ 55.795M Nov 12, 2026
MODL 0.06% 10,042 $ 642.788K Jun 30, 2026
DFUS 0.06% 161,433 $ 13.212M Nov 12, 2026
ACVF 0.05% 1,033 $ 70.265K Jul 31, 2026
DCOR 0.05% 253,571 $ 20.752M Nov 12, 2026
VOXP 0.04% 36 $ 2,448.72 Jul 31, 2026
VFVA 0.04% 5,326 $ 379.371K Aug 31, 2026
HCMT 0.04% 3,166 $ 215.351K Jul 31, 2026
NTSX 0.04% 8,072 $ 516.689K Jun 30, 2026
GDE 0.04% 2,445 $ 174.157K Aug 31, 2026
APUE 0.03% 10,782 $ 768.002K Aug 31, 2026
THRO 0.03% 38,628 $ 3.205M Nov 16, 2026
RAA 0.02% 2,145 $ 137.301K Jun 30, 2026
NTSD 0.02% 122 $ 7,809.22 Jun 30, 2026
CSHP 0.02% 927 $ 76.904K Nov 16, 2026
ENHU 0.02% 19 $ 1,576.24 Nov 16, 2026
AVLC 0.02% 3,328 $ 276.091K Nov 16, 2026
GSPY 0.02% 1,613 $ 133.814K Nov 17, 2026
EBI 0.01% 987 $ 70.304K Aug 31, 2026
IALT short -0.01% -13,179 $ -1.093M Nov 16, 2026
AAUS 0.01% 741 $ 60K Nov 18, 2026
NPFE 0.00% 66 $ 4,489.32 Jul 31, 2026
CORO 0.00% 285 $ 23.632K Nov 16, 2026